STUDY SEARCH RESULTS

1 study found for your search request:  2870-012

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-...
Condition: Triple-Negative Breast Cancer
Minimum Age: 18 years, Maximum Age: N/A
Gender: All
Study ID: NCT06393374
Status: Recruiting
Has Enrolling Locations in US or Canada




Copyright © 2026 · Merck & Co., Inc., Rahway, NJ, USA, and its affiliates. All rights reserved. · This site is intended only for residents of the United States.
Cookie Preferences  Privacy  Terms of Use  Consumer Health Data Privacy Policy  Your Privacy Choices   Accessibility  U.S. Corporate Site